Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Double-blind, Double-dummy Parallel Group Study to Compare the Efficacy and Safety of Fluticasone Propionate / Formoterol Fumarate (Flutiform(R)) 500/20 microg BID and 250/10 microg BID Versus Salmeterol / Fluticasone (Seretide(R)) 50/500 microg BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Randomised Double-blind, Double-dummy Parallel Group Study to Compare the Efficacy and Safety of Fluticasone Propionate / Formoterol Fumarate (Flutiform(R)) 500/20 microg BID and 250/10 microg BID Versus Salmeterol / Fluticasone (Seretide(R)) 50/500 microg BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 27 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2017 Primary endpoint has been met. (Average pre-dose FEV1), according to a Vectura media release.
    • 13 May 2016 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top